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Is screening for diabetes among tuberculosis patients 
feasible at the ﬁ eld level?
B. Naik,1 A. M. V. Kumar,2 S. Satyanarayana,2 M. D. Suryakant,3 N. M. V. Swamy,4 S. Nair,1 
P. Isaakidis,5 A. D. Harries6,7
and TB recommends bidirectional screening of the 
two diseases.6
A countrywide project was conducted in 2012 to 
better understand the optimal screening procedures, 
implementation, monitoring, results and challenges 
of screening patients with TB for DM within eight 
tertiary health care settings and more than 60 periph-
eral health institutions (PHIs). The aggregate data of 
the project have been reported elsewhere.7,8 In this ar-
ticle, we pre sent on a more individual basis the feasi-
bility and results of screening TB patients for DM in 
17 PHIs in a district of South India, and the challenges 
faced during implementation. 
METHODS
Design 
This was a descriptive study involving the implemen-
tation of DM screening procedures for TB patients in 
routine programmatic settings. 
Setting 
Bangarpet (population 0.5 million) is one of the Tu-
berculosis Units (TU) in the Kolar district in the south-
ern part of India. TB diagnosis and treatment ser-
vices are delivered in a decentralised manner at all the 
17 PHIs of the TU. Under India’s Revised National TB 
Control Programme (RNTCP), a PHI is deﬁ ned as any 
health facility with a sanctioned medical ofﬁ cer posi-
tion. All presumptive TB cases are investigated for the 
disease at the designated microscopy centres. After 
being diagnosed with TB, patients receive intermit-
tent treatment three times a week for a period of 6–
9 months, delivered under direct observation in ac-
cordance with national guidelines.9 TB patients are 
registered and followed up until completion of treat-
ment as per national guidelines. 
While facilities for DM screening are available at all 
PHIs, treatment services are provided only by the spe-
cialists at the district level hospital and are continued 
in the PHI closest to the patient. The average distance 
from the PHIs to the district hospital is 35 km. Patients 
had to travel to the specialist hospital at their own ex-
pense. The drugs for treating DM were available in the 
general pharmacy and dispensed by the hospital phar-
macist on prescription by the treating doctor. All ser-
vices for the diagnosis and treatment of DM were pro-
vided free of charge.
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Setting: Seventeen peripheral health institutions (PHI) in 
Kolar district (population: 0.5 million), South India. 
Objective: To assess the feasibility and results of screen-
ing patients with tuberculosis (TB) for diabetes mellitus 
(DM) at peripheral level.
Design: From January to September 2012, all TB patients 
were assessed for DM. Those with unknown DM status 
were screened for the disease (free of charge) by trained 
laboratory technicians at each PHI, using a glucometer sup-
plied by the national programme on a capillary blood sam-
ple. Those with fasting blood glucose (FBG) ⩾ 126 mg/dl 
(⩾7 mM) were diagnosed as DM-positive.
Results: Of 362 TB patients, 358 (99%) were assessed 
for DM and 62 (17.1%) had the diseases—53 (14.6%) 
had a previous history of DM and 9 (2.9%) were newly 
diagnosed. All new DM patients were enrolled into DM 
care. Higher DM prevalence was found among TB patients 
aged ⩾40 years, smokers and those with smear-positive 
pulmonary TB. To detect a new case of DM, the number 
needed to screen (NNS) among TB patients was 40. 
Conclusion: Screening of TB patients for DM was feasi-
ble and effective in a peripheral setting. The availability 
of trained laboratory technicians and free services at 
e very PHI made the intervention feasible. The study has 
contributed towards a national policy decision in this 
regard. 
The world is facing a new epidemic of non-c ommunicable diseases due to various factors 
such as urbanisation, a sedentary lifestyle, rising obe-
sity and other lifestyle factors. In 2012, there were an 
estimated 371 million people living globally with dia-
betes mellitus (DM), with numbers expected to rise to 
552 million by 2030.1 India is badly affected by the 
DM epidemic, with over 60 million people estimated 
to have the disease.1 
Previous studies have shown that people with DM 
have a higher risk of developing tuberculosis (TB) 
compared to those who do not have diabetes.2,3 Recent 
studies in India have also found a high prevalence of 
DM in TB patients.4,5 With a high DM burden in India, 
routine screening of TB patients for DM would appear 
to be worthwhile at all levels of care, including periph-
eral health facilities. A recently launched World Health 
Organization–International Union Against Tuberculo-
sis and Lung Disease (The Union) Framework for Col-
laborative Activities to reduce the dual burden of DM 
AFFILIATIONS
1 World Health Organization 
Country Office for India, 
New Delhi, India
2 International Union 
Against Tuberculosis and 
Lung Disease (The Union), 
South-East Asia Office, 
New Delhi, India 
3 State Tuberculosis Centre, 
Ministry of Health and 
Family Welfare, Govern-
ment of Karnataka, Banga-
lore, India 
4 District Tuberculosis 
Centre, Ministry of Health 
and Family Welfare, 
Government of Karnataka, 
Kolar, India
5 Médecins Sans Frontières, 
Mumbai, India
6 The Union, Paris, France 
7 London School of Hygiene 
& Tropical Medicine, 
London, UK 
CORRESPONDENCE
Balaji Naik
Office of the Joint Director (TB)
Lady Willingdon State TB 
Centre
4th Main Road
Sampangiramanagara
Bangalore 560 027, India
Tel: (+91) 93410 60148
e-mail: drbalajinaik@
gmail.com
KEY WORDS
tuberculosis; diabetes 
m ellitus; screening; 
op erational research; India
PHA 2013; 3(S1): S34–S37
© 2013 The Union
Received 3 May 2013
Accepted 28 May 2013
Public Health Action Field screening for diabetes in TB patients  S35
Study population
All TB patients registered from January to September 
2012 in 17 PHIs in Bangarpet TU were included in the 
study.
Diabetes mellitus screening, variables 
and data collection 
The methods of screening, diagnosis and referral of TB 
patients with DM to diabetes care have been described 
in detail elsewhere.8 Brieﬂ y, TB patients were asked 
if they had a history of DM. Among those with un-
known DM status, a random blood glucose (RBG) test 
was offered, followed by a fasting blood glucose (FBG) 
test if the RBG was ⩾110 mg/dl (⩾6.1 mM). Blood glu-
cose was assessed using a glucometer supplied by the 
National Programme for Prevention and Control of 
Cancer, Diabetes, Cardiovascular Disease and Stroke 
(NPCDCS) on a capillary blood sample. Those with an 
FBG ⩾126 mg/dl (⩾7 mM) were diagnosed with DM, 
and those with an FBG between 110 and 125 were di-
agnosed with pre-diabetes (impaired fasting glucose), 
in accordance with national guidelines.10 
Screening was performed by PHI laboratory tech-
nicians trained by NPCDCS district nodal ofﬁ cers as 
part of the strategy adopted by the NPCDCS to screen 
all people aged >30 years at the point of primary con-
tact with any health care facility. No additional staff 
were deployed for this project. Variables of interest to 
the study were sourced from the TB register and the 
TB-DM register.
Data analysis and statistics
Data were entered in duplicate into an EpiData soft-
ware package (EpiData entry version 3.1; EpiData As-
sociation, Odense, Denmark, http://www.epidata.dk), 
the databases were compared and discrepancies re-
solved by checking the original register. The propor-
tion of DM cases that were ‘newly diagnosed’ was cal-
culated. To find one additional DM case, the number 
needed to be screened (NNS) among TB patients was 
determined. All variables were described as propor-
tions, and differences between groups were compared 
for statistical significance using the χ2 test or Fisher’s 
exact test, as applicable. P values <0.05 were consid-
ered statistically significant.
Ethics approval
The protocol was reviewed and approved by The 
Union Ethics Advisory Group, Paris, France.
RESULTS
There were 362 patients registered in the TU, of whom 
68% were male. The median age of the cohort was 
40 years (interquartile range [IQR] 27–56), and the me-
dian age of females was 30 years (IQR 21–45) com-
pared to 45 years (IQR 32–60) among males. The re-
sults of screening are presented in Table 1. Of the 362 
TB patients, 358 (99%) were assessed for DM. More 
than 75% of the TB patients were found to have had 
their RBG tested within 3 days of starting TB treatment, 
and among those eligible for FBG, more than 75% had 
had their FBG tested within 6 days of the RBG. Among 
the 358 patients, 62 (17.1%) were found to have DM: 
53 (14.6%) had a previous history of DM and 9 (2.9%) 
were newly diagnosed. In addition, 11 patients were di-
agnosed with pre-diabetes. All newly diagnosed DM 
patients were referred and enrolled into DM care. 
Further analysis showed that the prevalence of 
DM among TB patients aged ⩾40 years was signiﬁ -
cantly higher than among patients aged <40 years 
(Table 2). There was a higher prevalence of DM in new 
smear-positive pulmonary TB patients compared with 
new extra-pulmonary TB cases, and in smokers com-
pared to non-smokers. 
TABLE 1 Screening patients with TB for DM at 17 
peripheral health institutions of the Bangarpet 
Tuberculosis Unit, Kolar, India, January–September 2012
Parameter n (%)
Patients registered with TB 362
Patients with known diagnosis of DM  53 (14.6)
Number needed to be screened with RBG 309
Patients screened with RBG 305 (98.7)
Patients with RBG ⩾110 mg/dl (⩾6.1 mM) 
  and needing to be screened with FBG 101
Patients screened with FBG  92
FBG results
 FBG <110 mg/dl (<6.1 mM)
 FBG ⩾110 to 125 mg/dl (⩾6.1 mM to 
  6.9 mM)
 FBG ⩾126 mg/dl (⩾7 mM)
 72
 11
  9
Newly diagnosed with DM*   9 (2.9)
Patients with known or newly diagnosed DM  62 (17.1)
Patients with newly diagnosed DM enrolled 
  in DM care   9 (100)
* Percentage of screened patients with TB with a new diagnosis of DM.
TB = tuberculosis; DM = diabetes mellitus; RBG = random blood glu-
cose; FBG = fasting blood glucose; mM = millimoles.
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TABLE 2 Prevalence of DM among TB patients according to 
different variables, Kolar District, India, January–September 2012
Characteristic
TB 
patients
n
Patients 
with DM
n (%) P value
Total 362 62 (17.1)
Age, years
 <40 173 10 (5.8) <0.01
 ⩾40 189 52 (27.5)
Sex
 Male 246 43 (17.5)   0.79
 Female 116 19 (16.4)
Type of TB
 New smear-positive 
  pulmonary TB 162 36 (22.2) <0.01
 New smear-negative 
  pulmonary TB  45  7 (15.6)   0.20
 New extra-pulmonary TB  95  8 (8.4) Reference
 Retreatment  60 11 (18.3)   0.07
Current smoker*
 Yes 157 34 (21.7)   0.04
 No 205 28 (13.7)
HIV status
 Positive  22  1 (4.5)   0.15
 Negative 340 61 (17.9)
* Current smoker = smoked in the last month.
DM = diabetes mellitus; TB = tuberculosis; HIV = human immuno deficiency 
virus.
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To detect a new case of DM, the NNS among TB patients was 
40 (Table 3). Among the new smear-positive TB patients, the NNS 
was 23 compared to 30 among previously treated TB cases. 
Some challenges were noted during the implementation of the 
screening process. There was a shortage of test kits (strips for the 
glucometer) for a brief period of 8 days, and the laboratory tech-
nicians used the expired strips, re-calibrating the glucometers. 
This was later rectiﬁ ed by the district programme manager of the 
NPCDCS, who obtained supplies of fresh batches of test strips.
DISCUSSION
This is part of the ﬁ rst nationwide study from India reporting on 
the feasibility and outcomes of routine screening of patients with 
TB for DM. The results of this current study suggest that it is feasi-
ble to implement routine screening of TB patients for DM at the 
peripheral level. Near-universal screening of TB patients shows that 
testing for DM is acceptable among TB patients. The availability 
of staff trained in using glucometers supplied by the NPCDCS and 
of free DM diagnostic and treatment services helped to make this 
intervention feasible, with no requirement for additional re-
sources. While most of the TB patients underwent RBG testing 
within 3 days of starting TB treatment, nearly 8% of those with 
RBG levels >110 mg/dl (6.1 mM) who were eligible for FBG did 
not return. The exact reasons for this are not clear, although it 
could be due to implementation problems in the initial stages of 
the pilot project. 
The overall prevalence of DM among TB patients was high, at 
17%, although lower than in other parts of South India.4,5 The ac-
tual prevalence could be much higher, as we used FBG to diag-
nose DM and it is well known that FBG is not as sensitive as the 
75 g oral glucose tolerance test (OGTT) and that it may miss cases 
of impaired glucose tolerance.11 A hospital-based study conducted 
in Karnataka State reported a DM prevalence of 30% among TB 
patients. This higher prevalence may be attributed to selection 
bias due to hospital-based sampling.12 Previous studies from other 
South Indian states, such as Kerala and Tamil Nadu, reported a 
prevalence of 44% and 25% respectively.4,5 As has been reported 
in earlier studies, patients aged >40 years and those with smear-
positive pulmonary TB had a higher prevalence of DM.4 Nearly 
44% of the TB patients were smokers, and DM prevalence was 
higher among smokers than non-smokers. As smoking and DM 
are risk factors for unfavourable TB treatment outcomes and 
health outcomes in general, this group needs special attention 
and should be linked to smoking cessation services in addition to 
DM care. We are planning to prospectively follow the whole co-
hort of this study population to examine the joint impact of DM 
and smoking on TB treatment outcomes.
Among the DM cases found in our study, the proportion of 
previously diagnosed DM was high, at 86%, compared to about 
50% in other studies of South India.4,5 This could be attributed to 
the fact that Kolar is one of the 100 districts in the country where 
the NPCDCS has launched a programme for early diagnosis of 
chronic non-communicable diseases by screening all persons aged 
>30 years at the point of primary contact with any health care fa-
cility.6 It is worth mentioning here that the RNTCP was quick to 
take advantage of the momentum of the screening programme 
launched by the NPCDCS and extend it to TB patients, with bene-
ﬁ ts for both national programmes. This universal screening strategy 
was one of the reasons for the relatively high NNS found in our 
study. Despite this fact, several new cases of DM and pre-diabetes 
were still found during our screening. Studies have shown that pa-
tients with pre-diabetes have a higher risk of developing type 2 DM, 
and they also need to be targeted for preventive interventions.13 
Several challenges were noted in the supply chain manage-
ment of glucometer strips, and some instances of strip shortages 
and expiry were experienced during ﬁ eld visits. The fact that labo-
ratory staff were using the glucometer strips after expiry indicates 
a need for training. The NPCDCS is still in its infancy, and mecha-
nisms need to be put in place to ensure uninterrupted supplies for 
smooth implementation of screening. 
One of the limitations of our study is that the results obtained 
by the expired strips could not be excluded from the analysis, as 
we could not ascertain the exact number of tests performed with 
the expired strips or on whom they were performed in that pe-
riod. Another limitation is the lack of conﬁ rmatory repeat FBG 
testing before making a diagnosis of DM, as recommended by the 
American Diabetes Association.13 We did not do this in our study, 
as this recommendation is not included in the national guidelines 
in India. We are not aware whether this was done at the point of 
enrolment into DM care and therefore cannot comment on the 
implications.
This study contributed to a policy decision made by the 
RNTCP in India to routinely offer DM screening for all TB patients. 
A plan for recording, reporting and monitoring this important in-
tervention has been prepared, and a training manual for health 
care providers has been drafted. There is now a need to monitor 
the roll-out of the intervention and lessons need to be learnt 
through ﬁ eld-based operational research. It is time to convert pol-
icy to practice and ensure implementation as per guidelines. 
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Contexte  :  Dix-sept institutions de santé périphériques (PHI) du Dis-
trict de Kolar (population: 0,5 million d’habitants), Inde du Sud. 
Objectif  :  Evaluer la faisabilité et les résultats du dépistage au niveau 
périphérique du diabète sucré (DM) chez les patients atteints de tu-
berculose (TB).
Schéma  :  Au cours de la période de janvier à décembre 2012, on a 
évalué tous les patients TB en matière de DM. Ceux dont le statut 
DM était inconnu ont été dépistés pour le DM (gratuitement) par un 
technicien entrainé de laboratoire dans chaque PHI sur un échantillon 
de sang capillaire, au moyen d’un glycomètre fourni par le pro-
gramme national. Ceux dont le glucose sanguin à jeun (FBG) était 
⩾126 mg/dl (⩾7 mM) ont été diagnostiqués comme DM. 
Résultats  :  Sur 362 patients TB, 358 (99%) ont été évalués pour DM 
et 62 (17,1%) souffraient de DM ; chez 53 (14,6%) le DM était déjà 
connu antérieurement et chez 9 (2,9%) le diagnostic de DM était 
nouveau. Tous les nouveaux patients DM ont été enrôlés pour des 
soins du DM. Une prévalence plus élevée de DM a été observée parmi 
les patients TB âgés de ⩾40 ans, parmi les fumeurs et chez ceux at-
teints d’une TB pulmonaire à frottis positif. Pour détecter un nouveau 
cas de DM, le nombre de personnes à dépister (NNS) chez les pa-
tients TB est de 40.
Conclusion  :  Le dépistage du DM chez les patients TB est réalisable et 
efficient dans un contexte périphérique. La disponibilité de tech-
niciens entrainés de laboratoire et le service gratuit dans chaque PHI 
ont rendu l’intervention réalisable. Cette étude a contribué à une dé-
cision politique nationale dans ce domaine. 
Marco de referencia: Diecisiete establecimientos sanitarios periféri-
cos en el Distrito de Kolar, que cuenta con una población de medio 
millón de habitantes en el sur de la India. 
Objetivo: Evaluar la factibilidad de introducir una detección si-
stemática de la diabetes (DM) en los pacientes con tuberculosis (TB) 
y analizar los resultados que aportaría esta iniciativa en el nivel 
periférico. 
Métodos: Entre enero y septiembre del 2012 se investigó en todos 
los pacientes con TB el diagnóstico de DM. En las personas que 
desconocían su situación frente a la DM, un técnico de laboratorio 
capacitado practicó el examen diagnóstico en cada establecimiento 
(sin costo alguno), en una muestra de sangre capilar, con el uso de 
un glucómetro que suministraba el programa nacional. Se estableció 
el diagnostico de DM en todos los pacientes con una glucemia en 
ayunas ⩾126 mg/dl (⩾7 mM/dl).
Resultados: De los 362 pacientes con TB se investigó la DM en 358 
(99%) y se estableció el diagnóstico en 62 casos (17,1%), de los 
c uales 53 (14,6%) conocían su diagnóstico y en nueve (2,9%) se 
trató de un diagnóstico nuevo. Todos los pacientes con diagnóstico 
reciente se inscribieron en el programa de atención de la DM. La 
mayor prevalencia de DM se observó en los pacientes TB a partir de 
los 40 años de edad, fumadores y que presentaban una TB pulmonar 
con baciloscopia positiva. Con el fin de detectar un nuevo caso de 
DM fue necesario practicar el cribado en 40 pacientes TB. 
Conclusión: Practicar la detección sistemática de la DM en los paci-
entes con diagnóstico de TB constituye una estrategia factible y eficaz 
en un centro periférico de salud. La presencia de técnicos de labora-
torio capacitados y de servicios sin costo alguno en cada estableci-
miento periférico hizo posible la intervención. El estudio contribuyó a 
una decisión de política nacional en este sentido. 
